An immune checkpoint inhibitor (IO) that targets programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and CTLA-4 is an important therapeutic agent for NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.